Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Pancreatoduodenectomy is the standard procedure for duodenal carcinoma of the third or fourth portion. As an alternative option, we developed a novel segmental resection (SR) with partial mesopancreatic and mesojejunal excision (pMME) that enhances radicality. In this report, the surgical technique with video and outcomes are described.

Method: We performed SR with pMME on seven consecutive patients with third or fourth duodenal carcinoma between 2009 and 2021. We divided the procedure into four sections, including (1) wide Kocher's maneuver, (2) supracolic anterior artery-first approach, (3) dissection of the mesopancreas and mesojejunum, and (4) devascularization of the uncinate process and dissection of duodenum.

Result: Median operative time was 348 min (range, 222-391 min), and median blood loss was 100 mL (range, 30-580 mL). Major complications of Clavien-Dindo classification grade 3a or more occurred in one patient. All patients achieved R0 resections with 10 mm or more proximal margin. Six cases (85%) were alive without recurrence.

Conclusion: We developed a radical and safe procedure of SR with pMME as an alternative and less invasive approach for duodenal carcinoma of the third or fourth portion.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00423-022-02569-7DOI Listing

Publication Analysis

Top Keywords

duodenal carcinoma
16
third fourth
16
carcinoma third
12
fourth portion
12
segmental resection
8
resection partial
8
partial mesopancreatic
8
mesopancreatic mesojejunal
8
mesojejunal excision
8
excision pmme
8

Similar Publications

Introduction: von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary disorder characterized by the development of tumor-like lesions in multiple organs. While central nervous system hemangioblastomas, pancreatic neuroendocrine tumors, and pancreatic cysts are commonly associated with VHL disease, there have been few reported cases of pancreatic hemangioblastoma in patients with VHL disease.

Case Presentation: A male patient in his 30s had been diagnosed with VHL disease and had been followed for cerebellar and spinal hemangioblastomas, and renal cell carcinoma, for which he had undergone several tumor resections, radiation therapy, and a ventriculoperitoneal shunt.

View Article and Find Full Text PDF

Objective: To demonstrate the effectiveness and safety of intraluminal endoscopic treatment of patients with adenomas of the major duodenal papilla and familial adenomatous polyposis.

Material And Methods: Over the past 4 years, 13 patients with adenomas of the major duodenal papilla and familial adenomatous polyposis underwent surgery in our hospital. Of these, 7 patients had exclusively extrapapillary adenomas without signs of spread to the ducts.

View Article and Find Full Text PDF

Background: Cancer of unknown primary (CUP) is a challenging malignancy characterized by metastatic tumors with an unidentified primary site, even after extensive pathological and radiographic evaluation. Recent advancements in gene expression profiling and comprehensive genomic profiling (CGP) using next-generation sequencing (NGS) have enabled the identification of potential tissue origins, thereby facilitating personalized treatment strategies. Although most cases of CUP present as adenocarcinomas or poorly differentiated tumors, the treatment remains largely empirical, with limited success from molecularly tailored therapies.

View Article and Find Full Text PDF

Introduction: The most common etiology of large bowel obstruction (LBO) is colorectal cancer. However, extrinsic compression may occur from cancer of other organs. Plasmacytoid urothelial carcinoma (PUC) is a rare subtype of urothelial carcinoma that can present aggressively as an intraperitoneal spread.

View Article and Find Full Text PDF

Background/aim: Endoscopic submucosal dissection (ESD) can be performed to treat laterally spreading duodenal papillary tumors (LSPTs). However, no studies have been conducted on the outcomes of ESDs for LSPTs.

Methods: We retrospectively compared 47 patients who underwent endoscopic papillectomies (EPs) for papillary tumors (PTs) between June 2007 and July 2023 (EP group) and eight patients who underwent ESDs for LSPTs between February 2022 and July 2023 (ESD group).

View Article and Find Full Text PDF